Life Science News

AUPH INVESTOR NOTICE: ROSEN, A TOP RANKED LAW FIRM, Encourages Aurinia Pharmaceuticals Inc. Investors with Losses to Inquire About Securities Class Action Investigation - AUPH

-

Rosen Law Firm, P.A. Logo

WHY: Rosen Law Firm, a global investor rights law firm, continues its investigation of potential securities claims on behalf of shareholders of Aurinia Pharmaceuticals Inc. (NASDAQ: AUPH) resulting from allegations that Aurinia may have issued materially misleading business information to the investing public.

SO WHAT: If you purchased Aurinia securities you may be entitled to compensation without payment of any out of pocket fees or costs through a contingency fee arrangement. The Rosen Law Firm is preparing a class action seeking recovery of investor losses.

WHAT TO DO NEXT: To join the prospective class action, go to https://rosenlegal.com/submit-form/?case_id=3851 or call Phillip Kim, Esq. toll-free at 866-767-3653 or email pkim@rosenlegal.com or cases@rosenlegal.com for information on the class action.

WHAT IS THIS ABOUT: On February 28, 2022 , Aurinia issued a press release announcing its financial results for the quarter and full year ended December 31 , 2021.  Among other items, Aurinia reported a year-over-year revenue decline and announced a lower-than-expected sales outlook for 2022.

On this news, Aurinia's stock price fell $3.94 per share, or 24%, to close at $12.30 per share on February 28, 2022 , damaging investors.

WHY ROSEN LAW: We encourage investors to select qualified counsel with a track record of success in leadership roles. Often, firms issuing notices do not have comparable experience, resources, or any meaningful peer recognition. Many of these firms do not actually litigate securities class actions.  Be wise in selecting counsel. The Rosen Law Firm represents investors throughout the globe, concentrating its practice in securities class actions and shareholder derivative litigation. Rosen Law Firm has achieved the largest ever securities class action settlement against a Chinese Company. Rosen Law Firm was Ranked No. 1 by ISS Securities Class Action Services for number of securities class action settlements in 2017. The firm has been ranked in the top 4 each year since 2013 and has recovered hundreds of millions of dollars for investors. In 2019 alone the firm secured over $438 million for investors. In 2020, founding partner Laurence Rosen was named by law360 as a Titan of Plaintiffs' Bar. Many of the firm's attorneys have been recognized by Lawdragon and Super Lawyers.

Follow us for updates on LinkedIn: https://www.linkedin.com/company/the-rosen-law-firm , on Twitter: https://twitter.com/rosen_firm or on Facebook: https://www.facebook.com/rosenlawfirm/ .

Attorney Advertising. Prior results do not guarantee a similar outcome.

Contact Information:
Laurence Rosen, Esq.
Phillip Kim, Esq.
The Rosen Law Firm, P.A.
275 Madison Avenue, 40th Floor
New York, NY 10016
Tel: (212) 686-1060
Toll Free: (866) 767-3653
Fax: (212) 202-3827
lrosen@rosenlegal.com
pkim@rosenlegal.com
cases@rosenlegal.com
www.rosenlegal.com

Cision View original content to download multimedia: https://www.prnewswire.com/news-releases/auph-investor-notice-rosen-a-top-ranked-law-firm-encourages-aurinia-pharmaceuticals-inc-investors-with-losses-to-inquire-about-securities-class-action-investigation--auph-301511025.html

SOURCE Rosen Law Firm, P.A.

News Provided by PR Newswire via QuoteMedia

AUP:CA,AUPH

Aurinia Pharmaceuticals Announces Allowance of a New and Refined Method of Use Patent for LUPKYNIS® in the Treatment of Lupus Nephritis From the United States Patent and Trademark Office

Aurinia Pharmaceuticals Inc. (NASDAQ: AUPH) (Aurinia or the Company) today announced that the United States Patent and Trademark Office (USPTO) has allowed a method of use patent application titled IMPROVED PROTOCOL FOR TREATMENT OF LUPUS NEPHRITIS. Aurinia's newly allowed U.S. Patent Application (No. 17/713,140) reflects the unique and proprietary dosing regimen of its currently marketed product, LUPKYNIS. Specifically, this patent further refines the method of using LUPKYNIS in combination with mycophenolate mofetil (MMF) and corticosteroids using eGFR as a method of pharmacodynamically dosing the product in patients with lupus nephritis. The newly allowed application provides patent coverage that supplements Aurinia's existing U.S. Patent No. 10,286,036, which is listed in the Orange Book and claims an FDA-approved method of using LUPKYNIS. The claims in this additional patent add further specificity on dosing consistent with the FDA approved product label. This patent has the potential to provide an additional layer of patent protection for LUPKYNIS up to 2037. The Company intends to list this newly allowed patent in the Orange Book once issued.

News Provided by Business Wire via QuoteMedia

Keep reading...Show less
hands holding a 3D rendering of a double helix

Biotech Market Forecast: 3 Top Trends That Will Affect Biotech in 2023

Pull quotes were provided by Investing News Network clients Avricore Health and Sirona Biochem. This article is not paid-for content.

Nearly every industry faced financial difficulties in 2022. Even biotech, which as part of the healthcare sector often has more resilience to catastrophic market conditions, experienced struggles.

As investors look ahead to 2023, what trends could set the standard for the new year in the world of biotech?

Here the Investing News Network (INN) looks at what experts see coming for the biotech industry.

Keep reading...Show less

Gilead Sciences to Release Fourth Quarter & Full Year 2022 Financial Results on Thursday, February 2, 2023

Gilead Sciences, Inc. (Nasdaq: GILD) announced today that its fourth quarter and full year 2022 financial results and full year 2023 financial guidance will be released on Thursday, February 2 after the market closes. At 4:30 p.m. Eastern Time that day, Gilead's management will host a webcast to discuss the company's fourth quarter and full year 2022 financial results and provide a business update.

A live webcast will be available on the Investor Relations section of www.gilead.com and will be archived there for one year.

News Provided by Business Wire via QuoteMedia

Keep reading...Show less

The Robert A. Winn Diversity in Clinical Trials Award Program Established by the Bristol Myers Squibb Foundation to Expand with Amgen's Commitment of $8 Million

Amgen Joins Gilead Sciences as a Program Supporter

Applications Now Open for Physicians and Medical Students

News Provided by Business Wire via QuoteMedia

Keep reading...Show less
Boosh Consolidates Production to Improve Gross Margins

Boosh Consolidates Production to Improve Gross Margins

Boosh Plant-Based Brands Inc. (CSE: VEGI) (OTCQB: VGGIF) (FSE: 77I) ("Boosh" or the "Company") a premier plant-based brand in the "better for you" food sector, is pleased to announce that it has closed a small production facility in Penticton that it gained through the acquisition of Pulse Kitchen last year.

Boosh is moving production of those lines to Plant Veda Inc., (CSE: MILK) a premier producer of plant based milk and yogurt located in Delta BC.

News Provided by Newsfile via QuoteMedia

Keep reading...Show less

JUVÉDERM® VOLUX XC FOR IMPROVEMENT OF JAWLINE DEFINITION NOW AVAILABLE NATIONWIDE

With JUVÉDERM ® VOLUX™ XC, You Can Receive Non-Surgical Jawline Augmentation in Your Aesthetic Provider's Office

Today, Allergan Aesthetics, an ABBVie company (NYSE: ABBV), announced the highly anticipated national launch of JUVÉDERM ® VOLUX™ XC. The long-lasting hyaluronic acid (HA) filler is now available at aesthetic practices for consumers over the age of 21 with moderate to severe loss of jawline definition. 1

News Provided by PR Newswire via QuoteMedia

Keep reading...Show less

Latest Press Releases

Related News

×